3,5-Diiodothyropropionic Acid (Synonyms: DITPA) |
Catalog No.GC18696
One-Click Copy Product Info
|
3,5-Diiodothyropropionic acid는 갑상샘 호르몬 유사체로 α-myosin 중쇄 mRNA 발현을 유도하고 갑상샘 호르몬 수용체(TR)에 결합하며, TRα1 및 TRβ1에 대한 Ka는 각각 2.40 및 4.06 M-1입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1158-10-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
3,5-Diiodothyropropionic Acid is a synthetic thyroid hormone analog/thyromimetic. 3,5-Diiodothyropropionic Acid binds to thyroid hormone receptors (TRs) with association constants (Ka) of 2.40M-1 and 4.06M⁻¹ for TRα1 and TRβ1. 3,5-Diiodothyropropionic Acid promotes coronary arteriolar and microvascular angiogenesis by modulating pro‑angiogenic pathways such as VEGF, bFGF, and angiopoietin‑1/Tie‑2. 3,5-Diiodothyropropionic Acid can be used in studies on heart failure, angiogenesis and coronary microvascular remodeling, as well as thyroid hormone signaling related to lipid metabolism and metabolic‑endocrine regulation[1-4].
In vitro, 3,5-Diiodothyropropionic Acid (1–10ng/mL) was incubated with oligodendrocyte precursor cells or immature oligodendrocytes (OPCs/pre‑OLs) for 7–21 days. 3,5-Diiodothyropropionic Acid upregulated the expression of oligodendrocyte differentiation‑associated transcription factors (SOX10, OLIG1, OLIG2, etc.) and myelin genes (MBP, PLP1)[5]. 3,5-Diiodothyropropionic Acid (218nM) was applied to fetal rat cardiomyocytes for 48h. 3,5-Diiodothyropropionic Acid significantly upregulated genes involved in myocardial contraction and calcium cycling, including sarcoplasmic reticulum Ca²⁺‑ATPase, α‑MHC, BNP, proBNP, GLUT4, and the Na⁺/K⁺‑ATPase β1 subunit; 3,5-Diiodothyropropionic Acid significantly downregulated β‑MHC and aldolase C[6].
In vivo, 3,5-Diiodothyropropionic Acid (400ng/g or 4000ng/g; 2μL/g; once daily; subcutaneous injection) was administered to Mct8/Oatp1c1 double‑knockout (Dko) C57Bl/6N mice from postnatal day 1 to day 20. At 4000ng/g, 3,5-Diiodothyropropionic Acid restored normal myelination and cerebellar development in Dko mice[7]. 3,5-Diiodothyropropionic Acid (3mg/kg/day; once daily) was injected intraperitoneally into Mct8‑deficient (Mct8KO) C57BL/6 mice and wild‑type mice for 10 consecutive days. 3,5-Diiodothyropropionic Acid significantly reduced the elevated serum T₃ and rT₃ in Mct8‑deficient mice to wild‑type levels, lowered TSH. 3,5-Diiodothyropropionic Acid brought the previously elevated parameters of water intake, food intake, total energy expenditure, respiratory exchange ratio, and glucose oxidation fully back to the wild‑type range. In the liver, 3,5-Diiodothyropropionic Acid significantly downregulated positively regulated thyroid hormone target genes (Dio1, Me1, Gpd2) and upregulated the negatively regulated gene Gstα2, thereby ameliorating the peripheral thyrotoxic state caused by Mct8 deficiency[8].
References:
[1] Pennock GD, Raya TE, Bahl JJ, et al. Cardiac effects of 3,5-diiodothyropropionic acid, a thyroid hormone analog with inotropic selectivity. J Pharmacol Exp Ther. 1992 Oct;263(1):163-9.
[2] Nabbout LA, Robbins RJ. The cardiovascular effects of hyperthyroidism. Methodist Debakey Cardiovasc J. 2010 Apr-Jun;6(2):3-8.
[3] Spooner PH, Thai HM, Goldman S, et al. Thyroid hormone analog, DITPA, improves endothelial nitric oxide and beta-adrenergic mediated vasorelaxation after myocardial infarction. J Cardiovasc Pharmacol. 2004 Oct;44(4):453-9.
[4] Abohashem-Aly AA, Meng X, Li J, et al. DITPA, a thyroid hormone analog, reduces infarct size and attenuates the inflammatory response following myocardial ischemia. J Surg Res. 2011 Dec;171(2):379-85.
[5] Lee JY, Kim MJ, Deliyanti D, et al. Overcoming Monocarboxylate Transporter 8 (MCT8)-Deficiency to Promote Human Oligodendrocyte Differentiation and Myelination. EBioMedicine. 2017 Nov;25:122-135.
[6] Verge CF, Konrad D, Cohen M, et al. Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency. J Clin Endocrinol Metab. 2012 Dec;97(12):4515-23.
[7] Chen J, Salveridou E, Liebmann L, et al. Triac Treatment Prevents Neurodevelopmental and Locomotor Impairments in Thyroid Hormone Transporter Mct8/Oatp1c1 Deficient Mice. Int J Mol Sci. 2023 Feb 9;24(4):3452.
[8] Ferrara AM, Liao XH, Ye H, et al. The Thyroid Hormone Analog DITPA Ameliorates Metabolic Parameters of Male Mice With Mct8 Deficiency. Endocrinology. 2015 Nov;156(11):3889-94.
| Cell experiment [1]: | |
Cell lines | Fetal rat cardiomyocytes (ventricular myocytes) |
Preparation Method | Cells were plated and maintained in medium supplemented with fetal bovine serum pre‑stripped of thyroid hormone by passage over AG‑1 anion‑exchange resin. After reaching ~70% confluence (~48h post‑plating), cultures were switched to treatment: 3,5-Diiodothyropropionic Acid (dissolved in vehicle) was added at a concentration of 218nM. |
Reaction Conditions | 218nM; 48h |
Applications | 3,5-Diiodothyropropionic Acid recapitulated the T₃‑regulated transcriptional program in cardiomyocytes. 3,5-Diiodothyropropionic Acid up‑regulated contractile/calcium‑cycling genes (α‑MHC, SERCA2a/ATP2A2, BNP/Nppb, Nppa, GLUT4, Na⁺/K⁺‑ATPase β1) and suppressed fetal‑type β‑MHC, shifting the cardiomyocyte toward an adult, positive‑inotropic phenotype while inducing only minor divergences from T₃ (e.g. matrin 3and presenilin‑2). |
| Animal experiment [2]: | |
Animal models | C57BL/6J mice-wild-type (WT) and Mct8-deficient (Mct8KO) |
Preparation Method | Mice were individually placed in an open-circuit indirect calorimetry system for continuous recording. After a baseline period, mice received daily i.p. injections of 3,5-Diiodothyropropionic Acid. At endpoint, mice were euthanized and brain, liver, soleus, and gastrocnemius collected for qPCR of thyroid hormone–responsive genes. |
Dosage form | 3mg/kg/day; i.p.; once daily for 10 consecutive days |
Applications | 3,5-Diiodothyropropionic Acid significantly lowered serum T₃ and rT₃ in Mct8-deficient mice back to wild-type levels, while also reducing TSH; 3,5-Diiodothyropropionic Acid brought elevated metabolic parameters like water intake, food intake, total energy expenditure, respiratory exchange ratio, and glucose oxidation back down to normal levels; in the liver, 3,5-Diiodothyropropionic Acid notably downregulated positive thyroid hormone target genes like Dio1, Me1, and Gpd2, and upregulated the negatively regulated gene Gstα2, improving the peripheral thyrotoxic state caused by Mct8 deficiency. |
References: | |
| Cas No. | 1158-10-7 | SDF | |
| Synonyms | DITPA | ||
| Chemical Name | 4-(4-hydroxyphenoxy)-3,5-diiodo-benzenepropanoic acid | ||
| Canonical SMILES | IC1=CC(CCC(O)=O)=CC(I)=C1OC2=CC=C(O)C=C2 | ||
| Formula | C15H12I2O4 | M.Wt | 510.1 |
| Solubility | DMSO : 50 mg/mL (98.03 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9604 mL | 9.802 mL | 19.604 mL |
| 5 mM | 392.1 μL | 1.9604 mL | 3.9208 mL |
| 10 mM | 196 μL | 980.2 μL | 1.9604 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)